8-K: Aptose Q3 2025: Tuspetinib Shows Strong AML Responses

Aptose Biosciences reported strong clinical trial results for its AML drug tuspetinib, showing 100% complete responses at higher doses, despite significant cash flow challenges.

Summary

• Aptose Biosciences reported financial results for the third quarter ended September 30, 2025, and provided a corporate update on its lead drug candidate, tuspetinib.
• The TUSCANY clinical trial for tuspetinib (TUS) in combination with venetoclax (VEN) and azacitidine (AZA) (TUS+VEN+AZA) for newly diagnosed AML patients demonstrated excellent safety and high response rates.
• Patients treated at higher dose levels of 80 mg and 120 mg TUS achieved complete response/complete response with partial hematologic recovery (CR/CRh) in 100% (6/6) of cases, surpassing the 66% rate expected from VEN+AZA alone.
• Overall, 90% (9/10) of patients in the TUSCANY trial achieved CR/CRh responses across diverse mutational subtypes, including unmutated FLT3, FLT3-ITD, NPM1c, biallelic TP53 with complex karyotype, RAS, and myelodysplasia related mutations.
• MRD-negativity was observed in 78% (7/9) of responding patients by central flow cytometry, and two patients have undergone hematopoietic stem cell transplants (HSCT).
• The company has successfully dose escalated to the 160 mg TUS dose level in the triplet therapy.
• Net loss for the third quarter of 2025 decreased by $1.8 million to $5.1 million, compared to $7.0 million for the comparable period in 2024.
• Research and development expenses decreased by $2.5 million to $2.2 million for the third quarter of 2025, primarily due to reduced activity in the APTIVATE clinical trial, lower manufacturing activity, and the discontinuation of APTO-253.
• Cash, cash equivalents, and restricted cash equivalents stood at $1.6 million as of September 30, 2025, a significant decrease from $6.7 million at December 31, 2024.
• The company reported a working capital deficit of $3.3 million and a shareholders' deficit of $19.5 million as of September 30, 2025.
• Aptose explicitly stated it does not have sufficient cash to fund operations and relies on advances made by Hanmi, actively pursuing financing and cost reduction efforts to extend its cash runway.

Sentiment

Score: 6

Explanation: The clinical trial results for tuspetinib are exceptionally positive, demonstrating high efficacy and safety in a challenging patient population, which is a significant scientific and medical achievement. However, the company's dire financial situation, with critically low cash reserves and an explicit statement of insufficient cash to fund operations, introduces substantial financial risk and uncertainty, tempering the overall positive sentiment from the clinical data.

Positives

• Tuspetinib in combination with VEN+AZA demonstrated excellent safety and high activity in newly diagnosed AML patients, including those with adverse mutations.
• 100% (6/6) of patients treated at higher dose levels (80 mg and 120 mg TUS) achieved CR/CRh responses, significantly exceeding the 66% rate expected from VEN+AZA alone.
• Overall, 90% (9/10) of patients achieved CR/CRh responses across diverse mutational subtypes, including challenging ones like biallelic TP53 with complex karyotype.
• 78% (7/9) of responding patients achieved MRD-negativity, indicating deep and durable responses.
• Two patients have successfully completed hematopoietic stem cell transplants (HSCT), demonstrating the therapy's potential to enable curative options.
• The company successfully dose escalated to 160 mg TUS, indicating continued tolerability and potential for further efficacy.
• Net loss decreased by $1.8 million in Q3 2025 to $5.1 million and by $6.1 million for the nine months ended September 30, 2025, to $17.7 million, compared to the prior year periods.
• Research and development expenses decreased significantly by $2.5 million in Q3 2025 and $7.7 million for the nine months ended September 30, 2025, reflecting strategic program adjustments and cost reduction efforts.

Negatives

• Cash, cash equivalents, and restricted cash equivalents significantly decreased to $1.6 million as of September 30, 2025, from $6.7 million at December 31, 2024.
• The company reported a working capital deficit of $3.3 million as of September 30, 2025, a deterioration from a positive working capital of $5.0 million at December 31, 2024.
• A shareholders' deficit of $19.5 million was reported as of September 30, 2025, worsening from a $4.5 million deficit at December 31, 2024.
• The company explicitly stated it "does not have sufficient cash to fund operations" and relies on advances made by Hanmi.
• Long-term liabilities increased to $18.7 million as of September 30, 2025, from $10.2 million at December 31, 2024.
• The reduction in R&D expenses is partly due to reduced activity in the APTIVATE clinical trial and the discontinuation of APTO-253, which could be interpreted as a narrowing of the development pipeline.

Risks

• Ability to obtain the capital required for research and operations.
• Inherent risks in early-stage drug development, including demonstrating efficacy.
• Development time/cost and the regulatory approval process.
• The progress of clinical trials.
• Ability to find and enter into agreements with potential partners.
• Ability to attract and retain key personnel.
• Changing market and economic conditions.
• Unexpected manufacturing defects.
• The evolving regulatory and political landscape and the funding of government programs.

Future Outlook

The company anticipates providing further updates on the TUSCANY trial, including evolving response rates, durability data from four dose levels (40, 80, 120, and 160 mg), and safety/tolerability of tuspetinib with unadjusted VEN+AZA dosing at the upcoming 67th American Society of Hematology (ASH) Annual Meeting in December 2025. Management is actively deploying financing and cost reduction efforts to extend the cash runway.

Management Comments

• "Tuspetinib in combination with VEN+AZA standard treatment (TUS+VEN+AZA) has been highly active and so well tolerated in newly diagnosed AML patients with 40 mg, 80 mg, and 120 mg TUS, we dose escalated to the 160 mg TUS dose level in the triplet."
• "Patients evaluated at the higher dose levels of 80 mg and 120 mg TUS have all (6/6; 100%) achieved CR/CRh responses, exceeding the 66% rate expected from VEN+AZA alone."
• "We now are dosing at 160 mg TUS, and we look forward to providing further updates next month at ASH."

Industry Context

Aptose Biosciences operates in the highly competitive and capital-intensive precision oncology sector, specifically targeting acute myeloid leukemia (AML). The positive clinical data for tuspetinib, particularly the 100% CR/CRh rate at higher doses and MRD-negativity across diverse mutations, positions it as a potentially significant advancement in AML treatment, a disease with high unmet medical needs. The combination therapy approach with established drugs like venetoclax and azacitidine is a common strategy to improve efficacy and overcome resistance in oncology. However, the significant cash burn and reliance on external financing are common challenges for clinical-stage biotech companies, especially those without commercialized products.

Comparison to Industry Standards

• The 100% CR/CRh response rate observed in 6/6 patients at 80 mg and 120 mg TUS doses significantly exceeds the 66% rate typically expected from venetoclax and azacitidine (VEN+AZA) alone in newly diagnosed AML patients ineligible for induction chemotherapy.
• The overall 90% CR/CRh rate for TUS+VEN+AZA in the TUSCANY trial is highly competitive, especially considering responses across diverse and challenging mutational subtypes like biallelic TP53, which often indicate poor prognosis and resistance to standard therapies.
• The 78% MRD-negativity rate among responding patients suggests deep and durable responses, which is a critical benchmark for treatment success in AML and compares favorably to many existing therapies, indicating a high quality of response.
• The ability to achieve hematopoietic stem cell transplants (HSCT) in two patients further validates the efficacy of the triplet therapy in preparing patients for potentially curative options, a key goal in AML treatment.

Stakeholder Impact

• Shareholders: Potential for significant upside if financing is secured and clinical success continues, but high risk of dilution or even insolvency due to critical cash shortage and reliance on external advances.
• Patients: Positive clinical data offers hope for a new, highly effective treatment option for newly diagnosed AML, especially for those ineligible for induction chemotherapy and with adverse mutations.
• Employees: Uncertainty regarding job security due to the company's financial challenges and ongoing cost reduction efforts.
• Creditors: Increased risk due to the company's working capital and shareholders' deficit, and explicit reliance on external advances.
• Partners (e.g., Hanmi): Hanmi's advances are crucial for operations, indicating a significant role in the company's immediate future and potential for deeper collaboration or control.

Next Steps

• Report evolving response rate and durability data from four dose levels of TUS+VEN+AZA triplet at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition (December 6-9, 2025).
• Report safety and tolerability of TUS with VEN+AZA in combination with unadjusted dosing of VEN+AZA at ASH.
• Actively deploy financing and cost reduction efforts to extend cash runway.

Key Dates

Recommendation

The clinical data for tuspetinib is exceptionally strong, showing superior efficacy compared to standard therapy in a high-need oncology area. This fundamental scientific progress warrants a positive outlook on the drug's potential. However, the company's severe financial distress, explicitly stating insufficient cash to fund operations and a reliance on external advances, presents an immediate and critical risk. While the clinical news is a strong 'buy' signal on its own, the financial instability makes a 'strong buy' or 'buy' too risky without clarity on financing. A 'hold' recommendation acknowledges the significant clinical upside while cautioning investors about the imminent financial challenges and the need for successful capital raising to continue operations. Investors should monitor financing updates closely.

Keywords

Aptose Biosciences, Tuspetinib, AML, Acute Myeloid Leukemia, Oncology, Clinical Trial, TUSCANY, Venetoclax, Azacitidine, Precision Medicine, Hematology, Biotechnology, Drug Development, Financial Results, Q3 2025, ASH, ESH, CR/CRh, MRD-negativity, FLT3, TP53, Capital Raise, Cash Runway